Related references
Note: Only part of the references are listed.The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
W. Eiermann et al.
ANNALS OF ONCOLOGY (2013)
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER plus ) node-negative breast cancer
J. Albanell et al.
ANNALS OF ONCOLOGY (2012)
Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
Nathan W. D. Lamond et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Spontaneous Regression of Follicular Dendritic Cell Sarcoma
Donne Bennett De Leon Caces et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting
J. U. Blohmer et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Economic evaluation of the 21-gene signature (Oncotype DXA®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03)
Masahide Kondo et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Aebi et al.
ANNALS OF ONCOLOGY (2010)
Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection
Shelly S. Lo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization
Shmuel H. Klang et al.
VALUE IN HEALTH (2010)
Health-state utility values in breast cancer
Tessa Peasgood et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2010)
Predictors of return to work ten months after primary breast cancer surgery
Aina Johnsson et al.
ACTA ONCOLOGICA (2009)
The total hospital and community UK costs of managing patients with relapsed breast cancer
R. J. Thomas et al.
BRITISH JOURNAL OF CANCER (2009)
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
[Anonymous]
JOURNAL OF ONCOLOGY PRACTICE (2007)
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer - An economic analysis based on prognostic and predictive validation studies
Gary H. Lyman et al.
CANCER (2007)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Quality-of-life valuations of advanced breast cancer by New Zealand women
RJ Milne et al.
PHARMACOECONOMICS (2006)
A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation
BL Conner-Spady et al.
BONE MARROW TRANSPLANTATION (2005)
Share Paper
